Development of an anti-cotinine vaccine to potentiate nicotine-based smoking cessation strategies

J L Oliver, G Pashmi, P Barnett, P Mettens, R Biemans, P Monteyne, R Palmantier, T Gallagher, S Ramaya, S Wonnacott

Research output: Contribution to journalArticlepeer-review

16 Citations (SciVal)


Nicotine replacement therapies (NRT) have limited success in smoking cessation. The efficacy of nicotine may be compromised by its main metabolite, cotinine. An anti-cotinine vaccine to remove this antagonism could enhance the efficacy of NRT. We show that cotinine is a weak nicotinic a,agonist and decreases responses to nicotine, consistent with antagonism through receptor desensitisation. trans-4-Thiol cotinine was coupled to tetanus toxoid, and rats immunised repeatedly. Vaccination raised antibodies specific for cotinine that do not recognise other metabolites or nicotine. Increased serum cotinine concentrations following nicotine administration indicate sequestration of cotinine by antibodies. encouraging further evaluation of this vaccine in behavioural models of nicotine addiction and relapse.
Original languageEnglish
Pages (from-to)7354-7362
Number of pages9
Issue number42
Publication statusPublished - Oct 2007


Dive into the research topics of 'Development of an anti-cotinine vaccine to potentiate nicotine-based smoking cessation strategies'. Together they form a unique fingerprint.

Cite this